Andrew K. Balo Sells 5,000 Shares of DexCom Inc. (DXCM) Stock
DexCom Inc. (NASDAQ:DXCM) EVP Andrew K. Balo sold 5,000 shares of DexCom stock in a transaction dated Wednesday, October 5th. The stock was sold at an average price of $82.55, for a total value of $412,750.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Andrew K. Balo also recently made the following trade(s):
- On Wednesday, September 21st, Andrew K. Balo sold 5,000 shares of DexCom stock. The stock was sold at an average price of $92.87, for a total value of $464,350.00.
Shares of DexCom Inc. (NASDAQ:DXCM) opened at 82.93 on Friday. DexCom Inc. has a one year low of $47.92 and a one year high of $96.38. The company has a 50 day moving average of $90.88 and a 200-day moving average of $77.91. The firm’s market cap is $6.96 billion.
DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Tuesday, August 2nd. The medical device company reported ($0.24) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.12) by $0.12. DexCom had a negative net margin of 16.42% and a negative return on equity of 19.68%. The company earned $137.30 million during the quarter, compared to analyst estimates of $132.48 million. During the same quarter last year, the company posted ($0.05) EPS. The firm’s quarterly revenue was up 47.3% on a year-over-year basis. On average, analysts expect that DexCom Inc. will post ($0.57) EPS for the current year.
Several hedge funds and other institutional investors have recently made changes to their positions in DXCM. BNP Paribas Arbitrage SA raised its position in shares of DexCom by 3,320.0% in the third quarter. BNP Paribas Arbitrage SA now owns 1,197 shares of the medical device company’s stock worth $105,000 after buying an additional 1,162 shares during the last quarter. Bellwether Investment Group LLC acquired a new position in shares of DexCom during the second quarter worth about $119,000. Bank of Montreal Can acquired a new position in shares of DexCom during the second quarter worth about $134,000. CIBC Asset Management Inc acquired a new position in shares of DexCom during the second quarter worth about $211,000. Finally, ProShare Advisors LLC acquired a new position in shares of DexCom during the second quarter worth about $219,000. Hedge funds and other institutional investors own 99.37% of the company’s stock.
A number of equities research analysts recently weighed in on DXCM shares. Zacks Investment Research downgraded DexCom from a “hold” rating to a “strong sell” rating in a research report on Tuesday. Desjardins raised DexCom from a “hold” rating to a “buy” rating in a research report on Friday, September 16th. Benchmark Co. cut their price target on shares of DexCom from $106.00 to $86.00 and set a “buy” rating for the company in a research note on Wednesday, August 3rd. Jefferies Group restated a “positive” rating and set a $98.00 price target on shares of DexCom in a research note on Friday, July 22nd. Finally, BTIG Research cut shares of DexCom from a “buy” rating to a “neutral” rating and set a $92.00 price target for the company. in a research note on Wednesday, September 14th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $95.08.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.
Receive News & Stock Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related stocks with our FREE daily email newsletter.